Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
Condition: Primary Immunodeficiency Disease
MeSH terms: Primary Immunodeficiency Diseases; Immunologic Deficiency Syndromes
Intervention: IgG Next Generation (BT595)
Intervention MeSH terms: Immunoglobulins; gamma-Globulins; Immunoglobulins, Intravenous; Rho(D) Immune Globulin
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 81.0
Sex: All
Minimum age: 2 Years
Maximum age: 75 Years
Healthy volunteers: No

Summary:

      This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in
      treating patients with Primary Immunodeficiency (PID)
    

Eligibility criteria:

        Criteria for inclusion:

          1. Written informed consent/assent obtained from subjects/subjects' parent(s) or legally
             acceptable representative indicating that they understood the purpose of, and
             procedures required for the study and are willing to participate in it.

          2. Male or female, aged 2 through 75 years, inclusive.

          3. Diagnosis of PID with impaired antibody production, ie:

             - Diagnosis of common variable immunodeficiency (CVID) as defined by the European
             Society for Immunodeficiencies (ESID)/Pan American Group for Immunodeficiency (PAGID)
             diagnostic criteria.

             Or

             - X-linked agammaglobulinaemia (XLA) as defined by ESID/PAGID diagnostic criteria.

          4. Established replacement therapy with any immunoglobulin for intravenous administration
             (IVIg) reference preparation during the previous 6 months, including documentation of
             IgG trough levels.

          5. Established replacement therapy with a single IVIg reference preparation for ≥3 months
             prior to treatment start with BT595 at a 3 week (Q3W) or 4 week (Q4W) schedule with a
             constant IVIg dose that did not change by ±20% of the mean dose, regular dosage
             intervals, and at least 1 IgG trough level of ≥5 g/L during the previous 3 months.

        Criteria for exclusion:

          1. Pregnancy or unreliable contraceptive measures or lactation period (females only).

          2. Known intolerance to immunoglobulins or comparable substances (eg, vaccination
             reaction).

          3. Known intolerance to proteins of human origin or known allergic reactions to
             components of the study product.

          4. Participation in another clinical study within 30 days before entering the study or
             during the study and/or previous participation in this study.

          5. Employee or direct relative of an employee of the contract research organization, the
             study site, or Biotest.

          6. Acquired medical conditions known to cause secondary immune deficiency, such as
             chronic lymphatic leukemia, lymphoma, multiple myeloma, as well as protein losing
             enteropathies and hypoalbuminemia.

          7. Other medical condition, laboratory finding, or physical examination finding that
             precludes participation.

          8. Recent febrile illness that precludes or delays participation.

          9. Active infection and receiving antibiotic therapy for the treatment of this infection
             at the time of screening. Note: if the subject was deemed to be a screen failure due
             to a nonserious active infection requiring antibiotic therapy, the subject may have
             been rescreened after the initial screening.

         10. Therapy with systemic steroids or other immunosuppressant drugs at the time of
             enrollment (current daily use of corticosteroids, ie, >10 mg prednisone equivalent/day
             for >30 days. Intermittent corticosteroid use during the study was allowable, if
             medically necessary).

         11. History of thrombotic events (including myocardial infarction, cerebral vascular
             accident [including stroke], pulmonary embolism, and deep vein thrombosis) within the
             6 months before treatment start with BT595 or the presence of significant risk factors
             for thrombotic events.

         12. Therapy with live-attenuated virus vaccines within 3 months before start of the study.

         13. Selective, absolute immunoglobulin A (IgA) deficiency or known antibodies to IgA.

         14. Positive diagnosis of hepatitis B or hepatitis C.

         15. Positive human immunodeficiency virus (HIV) test.

         16. History of drug or alcohol abuse within the 12 months before treatment start with
             BT595.

         17. Inability or lacking motivation to participate in the study.